NCT06073860View on ClinicalTrials.gov

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

RecruitingOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

December 21, 2027

Study Completion Date

December 21, 2027

Conditions
Myelodysplastic SyndromeBeta Thalassemia
Interventions
DRUG

Luspatercept

According to the approved label

Trial Locations (2)

06234

TERMINATED

Local Institution - 0001, Seoul

RECRUITING

Novotech Laboratory Korea Co., Ltd., Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06073860 - A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia | Biotech Hunter | Biotech Hunter